A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Recruiting · Phase 1 · NCT06803680
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
At a glance
- Research payments reported, 2025
- $148,742
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-B455 (drug), Chemotherapy (drug)
- Dates
- Started 2025-03-18; completion 2028-04-29
- Results posted
- Not yet
The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion
From ClinicalTrials.gov, last updated 2026-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $148,742 in research payments for this study in 2025 (14 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alexander Philipovskiy, M.D., PH.D Medical Oncology · Sanford, FL
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- David C. Starks, MD Gynecologic Oncology · Sioux Falls, SD
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Florida Cancer Specialist (scri) - Fort Myers $69,700
- Avera Mckennan Hospital & University Health Center, SD $44,992
- Adventhealth Orlando, FL $34,050
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.